Stay updated with breaking news from Dox centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ . ....